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Statement of Translational relevance 
Lung cancer is the leading cause of cancer mortality worldwide. Patient outcome is closely 
linked to tumor stage at diagnosis and unfortunately, most lung cancer patients are diagnosed 
at late stages when a curative treatment is no longer possible. Using an integrative genome-
wide experimental method whereby hundreds of stage I patients from two independent lung 
cancer datasets were examined, we identified an epigenetic four-gene model with diagnostic 
value for detecting lung cancer. This DNA methylation signature was validated with a gene-
locus specific technique in three minimally and non-invasive independent cohorts. The 
combination of this highly sensitive and specific epigenetic model with standard clinical 
markers may help to improve lung cancer diagnosis and therefore decrease current mortality 
rates. 
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Abstract 
PURPOSE: Lung cancer remains as the leading cause of cancer-related death worldwide, 
mainly due to late diagnosis. Cytology is the gold standard method for lung cancer diagnosis in 
minimally-invasive respiratory samples, despite its low sensitivity. We aimed to identify 
epigenetic biomarkers with clinical utility for cancer diagnosis in minimally/non-invasive 
specimens to improve accuracy of current technologies. 
EXPERIMENTAL DESIGN: The identification of novel epigenetic-biomarkers in stage I lung 
tumors was accomplished using an integrative genome-wide restrictive analysis of two 
different large public databases.  DNA methylation levels for the selected biomarkers were 
validated by pyrosequencing in paraffin-embedded tissues and minimally-invasive and non-
invasive respiratory samples in independent cohorts.  
RESULTS: We identified nine cancer-specific hypermethylated genes in early-stage lung 
primary tumors. Four of these genes presented consistent CpG island-hypermethylation 
compared to non-malignant lung and were associated with transcriptional silencing. A 
diagnostic signature was built using multivariate logistic regression model based on the 
combination of four-genes: BCAT1, CDO1, TRIM58 and ZNF177. Clinical diagnostic value was 
also validated in multiple independent cohorts and yielded a remarkable diagnostic accuracy in 
all cohorts tested. Calibrated and cross-validated epigenetic model predicts with high accuracy 
the probability to detect cancer in minimally and non-invasive samples. We demonstrated that 
this epigenetic signature achieved higher diagnostic efficacy in bronchial fluids as compared 
with conventional cytology for lung cancer diagnosis. 
CONCLUSION: Minimally-invasive epigenetic biomarkers have emerged as promising tools for 
cancer diagnosis. The herein obtained epigenetic model in combination with current diagnostic 
protocols may improve early diagnosis and outcome of lung cancer patients. 
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Introduction 
Lung cancer is the main cause of death from cancer worldwide (1). Several factors are 
associated with the poor outcome of lung cancer patients. One of them is, despite recent 
advances, the scarcity of effective therapies achieving durable responses. Another —and even 
more important— factor is late diagnosis, since most lung tumors are detected at advanced 
stages of the disease (2). This is crucial, taking into account that survival rates drop 
substantially from early to late stages. 
In this context, the data reported by early observational studies and by the randomized 
National Lung Screening Trial (NLST) have shown that lung cancer screening with low-dose 
helical computed tomography (LDCT) is able to reduce lung cancer mortality, as significantly 
more cases can be detected in earlier stages (3). Last year the United States Preventive 
Services Task Force (USPSTF) issued the recommendation to implement annual lung cancer 
screening for smokers with the inclusion criteria of the NLST. Nevertheless, there are still a 
significant number of open questions and areas for optimization of the different aspects 
related to this screening strategy.  For example, there is a need for risk models and markers to 
improve the screening cost-benefit ratio by better selecting the screened population. 
Moreover, although the CT-based imaging is a very sensitive technique, its specificity is low, 
and it yields a large proportion of cases with indeterminate nodules, which may require further 
follow up or invasive procedures, which may turn out to be futile in the frequent case of these 
nodules being benign. Biomarkers for the correct classification of the indeterminate nodules 
and as an adjunct to the diagnostic procedure are a clear unmet clinical need (4,5).   
Epigenetic biomarkers, mainly DNA methylation, have emerged as one of the most promising 
approaches to improve cancer diagnosis and present several advantages as compared to other 
markers, such as gene expression or genetic signatures. DNA methylation alterations are 
covalent modifications that are remarkably stable and often occur early during carcinogenesis. 
 
6 
 
Additionally, DNA methylation can be detected by a wide range of sensitive and cost-efficient 
techniques even in samples with low tumor purity. This epigenetic modification can also be 
detected in different biological fluids which represents a promising tool for minimally and non-
invasive cancer detection (6). In recent years, different epigenetic candidates have been 
proposed, but none has reached the clinic yet, mainly due to the lack of large validation 
studies or the use of analytical methods difficult to standardize. Additionally, most studies 
were performed by single candidate-gene hypothesis-driven (7-11), although incipient 
genome-wide approaches are also appearing (12). Nowadays, high throughput epigenomic 
studies, that permit an unbiased data-driven research, have become a great tool for 
systematically dissecting the role of epigenetic variation in cancer with the potential of 
identifying novel and more robust biomarkers (13). 
Bronchoscopic examination and pathological assessment of cytological specimen is the most 
currently used diagnostic method. However, almost half of the cases remain occult, especially 
in peripherally located tumors (14).  This leads to additional invasive procedures, such as 
surgical lung biopsy or transthoracic needle biopsy associated with significant morbidity (15). 
The implementation of molecular biomarkers, including epigenetic and gene expression 
classifiers, in bronchial aspirates or sputum represents a promising approach to improve the 
accuracy of minimally and non-invasive neoplasm diagnosis (16,17). This kind of biomarkers 
can also be used to develop clinical tools such as nomograms, which allow calculating the 
probability of a clinical event. These predictive models can increase the individualized risk 
assessment compared with risk groups leading to a more personalized medicine (18). 
Here, we have identified and validated a signature of DNA methylation biomarkers already 
present in early stage lung cancer and globally absent in normal tissue.  For this purpose, we 
used two different datasets: the CURELUNG FP7 Consortium and the Cancer Genome Atlas 
(TCGA). Subsequently, we tested by pyrosequencing the selected biomarkers in several 
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independent case-control datasets (formalin-fixed paraffin-embedded tissues, bronchial 
aspirates, bronchioalveolar lavages and sputum samples). This study provides a novel 
epigenetic predictive model that may help to improve lung cancer diagnosis. 
Materials and methods  
Study design and participants 
This is a collaborative and retrospective study including data from publicly available datasets, 
formalin-fixed paraffin-embedded (FFPE) tissues, bronchial aspirates/lavages and sputum 
samples obtained from lung cancer patients and cancer free individuals, as they arrived to the 
laboratory and passed the technical quality checks. Genome-wide DNA methylation data for 
the discovery cohort (Infinium 450K array)  was downloaded from our previous published lung 
cancer dataset deposited at the Gene expression omnibus (GSE39279) (19) or from the TCGA 
data repository (lung adenocarcinoma LUAD or Lung squamous cell carcinoma LUSC). The 
Biologic validation of the selected methylation biomarkers was conducted by pyrosequencing 
in four independent cohorts. Lung validating cohorts were obtained from different institutions 
in Spain. i) A total of 201 FFPE samples were obtained from Health Institute Carlos III (ISCIII), 
Madrid and Centre for Applied Medical Research/ Hospital of the University of Navarre, 
(CIMA/CUN) Pamplona. Regarding minimally invasive samples, ii) 80 Bronchial aspirates and iv) 
98 sputums were obtained from Catalan Institute of Oncology and Bellvitge University 
Hospital, Barcelona. iii) 111 Bronchioalveolar lavages came from CIMA, Pamplona and Hospital 
of Talavera de la Reina, Talavera de la Reina. All DNA extractions form different specimens 
were developed and run by the same technicians to avoid interlaboratory variation. 
The study was approved by the corresponding institutional review board and patients signed 
up the informed consent to participate. The main clinic-characteristics of the different cohorts 
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are described in table 1 or have been also described previously, as is the case for the discovery 
cohort (Table 1).  
Procedures 
Preparation of lung specimens 
DNA was extracted from minimally and non-invasive specimens using a standard phenol 
chloroform extraction method. DNA from FFPE tissue blocks was extracted from two 
sequential unstained sections, each 10 µm thick. For each sample of tumor tissue, subsequent 
sections were stained with hematoxylin and eosin for histological confirmation of the presence 
(>50%) of tumor cells. Unstained tissue sections were deparaffinized, and DNA was extracted 
using the same protocol as for minimally invasive specimens. Extracted DNA was checked for 
integrity and quantity with 1.3% agarose gel electrophoresis and picogreen quantification, 
respectively. Bisulfite conversion of 500 ng of DNA for each sample was performed according 
to the manufacturer’s recommendation.  
Data prefiltering  
DNA methylation status of 450,000 CpG sites by using the Infinium 450K Methylation array was 
available at (19). Methylation score of each CpG was represented as beta (β) value and were 
previously normalized for color bias adjustment, background level adjustment and quantile 
normalization across arrays. Probes and sample filtering involved a two-step process for 
removing SNPs and unreliable betas with high detection p-value p>0.001. Sex chromosome 
probes were also removed. After the filtering, the remaining 409,219 CpGs were considered 
valid for the study. Stage I patients were selected coming up to 237 lung tumor patients and 25 
histologically non-tumor lung tissue samples (Fig. 1). 
Data filtering for hypomethylated CpGs in non-tumoral tissues 
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The choice of region to be studied is one of the critical challenges to establishing a DNA 
methylation biomarker that is clinically useful. The investigated region should ideally fulfill the 
following criteria: first, the region should be unmethylated in non-tumor cases and methylated 
in lung cancer cases; and second, the methylation levels of this region should clearly allow the 
classification of a sample as non-cancerous or cancerous (20,21). We set thresholds to select 
homogeneous unmethylated CpGs in non-tumor cases; 1) Average and median of beta values 
lower than 0.1 and 2) the percentil 90 for beta values of control donors lower than 0.2. Using 
these restrictive thresholds we obtained 133,444 filtered CpGs. 
 Differentially methylated CpG identification between tumor and non-tumor samples 
Differentially methylated CpGs between tumor and non-tumor groups were identified using 
the following procedure: for each probe/CpG, the sets of methylation β values T (belonging to 
the tumor samples: first group) and NT (belonging to the non-tumor lung tissue samples: 
second group) were compared. The following three measures were calculated:  
1) Differences in average beta-values between groups higher than a set threshold. 
 (MD = |μT – μNT|>0.20)  
2) Multiple testing correction p-value with 95% of confidence to assign significant 
differentially methylated sites.   
False discovery rate (FDR) with adjusted p-value < 0.05. 
3) To maximize differences between tumor and non-tumor group. Difference between 
quartile 1 in tumor group and quartile 3 in non-tumor should be higher that a selected 
cut-off.   P25 (tumor)-P75 (nom-tumor)>0.1 
To identify early-stage cancer-related epigenetic markers with diagnostic value for both 
subtypes together, these three criteria (1,2,3) were evaluated in three distinct comparisons 
based on histological subtypes.  
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a) Comparison: Adenocarcinoma (ADC) group (n:181) vs non-tumor group (n:25). 
Identified 29 differentially methylated CpGs (DMCpGs) specific for ADC 
(Supplementary table1A).  
b) Comparison: Squamous cell carcinoma (SCC) group (n:56) vs non-tumour group (n:25). 
Identified 78 DMCpGs specific for SCC (Supplementary table 1B). 
c) Comparison: Lung cancer (ADC and SCC)) (n:237) vs non-tumor group (n:25). Identified 
24 significant DMCpGs when both groups are analyzed together (Supplementary table 
1C).  
Differentially methylated CpGs were selected using an integrative approach to rank the 
Infinium probes based on their methylation status and the fulfillment of all the criteria (1,2,3) 
and in the three different comparisons (a,b,c). Finally, Venn diagram analysis output final 12 
common CpGs corresponding to 9 genes ranked by averaged z-score (Supplementary Fig. 1 and 
supplementary table 2). 
Pyrosequencing 
Pyrosequencing analyses to determine CpG methylation status were developed as previously 
described (19) to validate the results obtained from the arrays. Briefly, a set of primers for PCR 
amplification and sequencing were designed using a specific software pack (PyroMark assay 
design version 2.0.01.15). Primer sequences were designed to hybridize with CpG-free sites to 
ensure methylation-independent amplification (Supplementary Table 2A). DNA was converted 
using the EZ DNA Methylation Gold (ZYMO RESEARCH) bisulfite conversion kit following the 
manufacturer’s recommendations and used as a template for subsequent PCR step. PCR was 
performed under standard conditions with primers biotinylated to convert the PCR product to 
single-stranded DNA templates. We used the Vacuum Prep Tool (Biotage, Sweden) to prepare 
single-stranded PCR products according to manufacturer’s instructions. PCR products were 
observed at 2% agarose gels before pyrosequencing. Pyrosequencing reactions and 
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methylation quantification were performed in a PyroMark Q24 System version 2.0.6 (Qiagen) 
using appropriate reagents and protocols, and the methylation value was obtained from the 
average of the CpG dinucleotides included in the sequence analyzed, with a minimum of 3 
valid CpGs per primer. Only those average methylation values within the region analyzed with 
coefficient of variation lower than 1 were accepted as valid. Controls to assess correct bisulfite 
conversion of the DNA were included in each run, as well as sequencing controls to ensure the 
fidelity of the measurements.  
Statistical analysis 
Data were summarized by mean, standard deviation, median and first and third quartiles in 
the case of continuous variables and by relative and absolute frequencies in the case of 
categorical variables. Differences in expression values and methylation levels among groups 
were assessed using the non-parametric Wilcoxon rank sum test. Receiver Operating 
Characteristic (ROC) curves were used to assess the predictive capacity of each marker. Area 
under the curve (AUC) was computed for each ROC curve, and 95% confidence intervals (CI) 
were also estimated by bootstrapping with 1000 iterations. A predictive model for each 
sample type was built including all selected markers in a multivariable logistic regression 
model. ROC curves and AUC were also computed for the predictive models. Calibration of the 
models was assessed by plotting predicted vs. observed values obtained by bootstrap 
resampling of the original data. Internal validation of the models was performed using 10-fold 
crossvalidation. The final predictive models were represented in nomograms to facilitate their 
use by clinicians. Sensitivity and specificity were estimated at the optimal cut-off point 
according to Youden’s criterion. Additionally, the sensitivity and specificity curves were 
estimated for the whole range of predictions of the model to allow for personalized decisions 
in different clinical scenarios.  Globally, a two-tailed p-value of less than 0.05 was considered 
to indicate statistical significance. P-values were adjusted for multiple comparisons using the 
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FDR procedure by Benjamini and Hochberg. All statistical analyses were performed using R 
software (version 3.2.0) and the pROC R-package (version 1.7.3). 
Results 
Identification and validation of cancer-related methylated genes  
The discovery cohort consisted of 237 stage I non-small cell lung primary tumors (NSCLC) and 
25 non-tumoral matched lung tissues from the CURELUNG FP7 publicly available dataset (19). 
Differentially DNA methylated CpGs (DMCpGs) were identified by genome-wide DNA 
methylation analysis. In this cohort (Table 1A), lung ADC (n=181, 76.3%) was the most frequent 
histological subtype, followed by SCC (n=56, 23.6%). In order to obtain highly cancer-specific 
biomarkers, we focused our analysis in those regions deeply hypomethylated in non-tumoral 
tissues.  After data filtering and analysis with restrictive criteria (Supplementary Fig. 1, 
Supplementary Table 1 and 2), we obtained 12 significant DMCpGs common to both subtypes 
of NSCLC corresponding to 9 different genes. In cancer cells, hypermethylation in CpG islands 
(CGI) is a principal epigenetic mechanism for gene regulation that has been proposed as a 
relevant biomarker with diagnostic value (22). Therefore, the top 5 hypermethylated CGI-
containing genes were selected as candidate biomarkers for further validation in NSCLC: 
BCAT1, CDO1, TRIM58, ZNF177 and CRYGD (For extended explanation see materials, Fig. 1A 
and Supplementary Table 2B).  
To confirm these results, we evaluated the DMCpGs of the 5 selected biomarkers in an 
independent cohort (350 stage I NSCLC patients; 62 non-tumoral lung samples) from TCGA 
public database. The clinical characteristics of this cohort (Table 1B) resembled the previous 
discovery cohort, including 217 (62.1%) ADCs and 133 (37.9%) SCCs. As expected, the 
methylation levels of the 5 selected genes were similar to the discovery cohort with difference 
in median values for each gene (∆BCAT1: 59%; ∆CDO1: 40%;   ∆TRIM58: 50%;   ∆ZNF177: 46%;   ∆CRYGD: 
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40%) and all with p-values lower than 0.001 (Fig. 1B). In addition, no significant differences 
were found between ADCs and SCCs (Supplementary Fig. 2A). These data confirmed our 
previous results, suggesting that the methylation of the 5 selected biomarkers is a common 
feature for both NSCLC subtypes despite their differences at histological and molecular level. 
Epigenetic silencing of the cancer-specific hypermethylated genes in lung cancer primary 
tumors 
Gene expression analysis from the TCGA cohort samples showed a significantly decreased 
expression in BCAT1, CDO1, TRIM58 and ZNF177 (Fig. 1C). However, no expression values were 
detected for CRYGD and this gene was discarded for future analysis. Interestingly, expression 
results were also obtained for ADCs and SCCs separately (Supplementary Fig. 2B). Moreover, 
promoter hypermethylation of multiple consecutive CpGs is recognized as an important 
mechanism by which genes may be silenced in both physiologically and pathological conditions 
(23). This mechanism for gene silencing has also been shown to play a relevant functional role 
in the development and progression of many common human tumors (24). In this regard, 
analyzing the CURELUNG and TCGA datasets, we observed a similar methylation pattern 
between the significant DMCpGs of the selected biomarkers and their surrounding CpGs 
(Supplementary Fig. 3). These results reinforced the role of DNA methylation in the functional 
regulation of BCAT1, CDO1, TRIM58 and ZNF177. Importantly, the data obtained suggest that 
the methylation values of these four genes represent an epigenetic signature that may be 
relevant in early steps of lung carcinogenesis. 
Diagnostic utility of the epigenetic signature to detect lung cancer in primary tumors 
Once the epigenetic signature was established (BCAT1, CDO1, TRIM58 and ZNF177), we 
evaluated the ability of each individual biomarker of the four-gene panel to detect lung cancer 
in primary tumors by using pyrosequencing. This technique is a suitable approach in a clinical 
setting because it represents a quantitative and reproducible method able to detect multiple 
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CpGs not only in FFPE tissues but also in minimally and non-invasive samples as biological 
fluids. Therefore, an independent cohort of FFPE primary tumors (122 stage I NSCLC and 79 
non-malignant lung samples) was recruited and DNA methylation levels for all selected genes 
were determined by pyrosequencing. Clinical characteristics for this cohort are described in 
Table 1C. The four biomarkers had significantly higher levels of DNA methylation in tumor 
samples as compared to non-tumoral controls (Fig. 2A). Next, receiver operating 
characteristics (ROC) analysis was performed to assess the diagnostic value of each individual 
biomarker to detect lung cancer. Importantly, all the genes of the signature showed significant 
areas under the ROC curve (AUC) greater than 0.8 (AUCBCAT1=0.94, AUCCDO1=0.84, 
AUCTRIM58=0.97 and AUCZNF177=0.94), suggesting a great accuracy of these biomarkers for 
NSCLC diagnosis (Fig. 2B). Similarly, when samples were classified based on histological 
subtypes (ADC and SCC), we observed for all the biomarkers significant differences in 
methylation status (Supplementary Fig. 4A) and AUCs close to 1.0 (Supplementary Fig. 4B and 
4C). These results confirmed the diagnostic value of evaluating DNA methylation levels by 
locus-specific PCR based techniques, such as pyrosequencing.  
Validation of the epigenetic signature for lung cancer diagnosis using minimally-invasive 
respiratory samples: bronchial aspirates (BAS) and bronchioalveolar lavages (BAL)  
One of the most important aspects for early diagnostics is to identify markers associated with 
cancer using minimally-invasive methods for sample collection (25). In line, we collected an 
independent cohort of BAS from patients diagnosed with lung cancer (n= 51) and cancer-free 
patients (n= 29) (Table 1D). This cohort included different lung cancer subtypes, especially ADC 
and SCC. We compared by pyrosequencing the median methylation levels and generated ROC 
curves to assess the performance of each marker independently. Airways fluids from lung 
cancer patients presented significant differences in DNA methylation levels and high AUCs for 
all four genes (Fig. 3A and 3B). Combination of BCAT1, CDO1, TRIM58 and ZNF177 in a logistic 
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regression model yielded a significant AUC of 0.91 (95% CI [0.83, 0.98] p<0.001, Fig. 3C). 
Calibration of the model showed no evident deviations from the ideal identity slope (data not 
shown). Internal validation of the AUC estimate for this model yielded optimism corrected AUC 
of 0.90, showing high generalization of the predictive capacity of the model for future samples. 
There were also no evident differences in prediction accuracy among early and late tumor 
stages.  
A visual representation of the methylation profile for the genes included in the model is 
provided as a heatmap (Supplementary Fig. 5A). A nomogram based on the results of this 
model is proposed as a predictive tool for clinical diagnostic use. Results of the nomogram 
provide an individual probability (0%-100%) for suffering lung cancer for each patient 
(Supplementary Fig. 5B and materials and methods). Evaluation of the full range of predictions 
of the model shows that shifting the cut-off to POC=30% would yield a sensitivity of 100% and 
a specificity of 65.4% and shifting the cut-off to POC=80% would yield a sensitivity of 71.4% 
and a specificity of 92.3%. Sensitivity and specificity at the optimal cut-off (Probability Of 
Cancer; POC= 63%) were 84.6% and 81.0% respectively (Fig. 3D). It is important to point out 
that current protocols for lung cancer diagnosis are based mainly in bronchioalveolar cytology 
and further lung biopsy. There are cases where the cytology is doubtful or inconclusive. 
Moreover, there are a notable number of cases where cytology and biopsy are negative for 
cancer cells, but there is high suspicion of cancer. Our results not only improve the overall 
prediction accuracy of BAS cytology in this cohort (sensitivity=43.8%, specificity=100%), but 
also permit a flexible and personalized approach for the clinicians in every possible scenario by 
simply adapting the cut-off value of the probabilistic model.  In this sense, in our cohort 24 of 
51 tumor samples were misinterpreted as non-tumoral by the cytology test. However, using 
our predictive epigenetic model, 19 out of the 24 false negative cytologies (79%) would have 
been considered as positive setting our threshold at 50% probability of cancer (Supplementary 
table 3). Of note, the majority of them (16 of 24) with a predicted probability of cancer higher 
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than 80%. Also three of them were classified as borderline non-tumor, with a predicted 
probability of cancer between 40% and 50%. In these three doubtful cases, clinical patient 
manage would require further additional studies. This led us to propose our epigenetic 
signature as a useful clinical diagnostic tool in BAS specimens, especially in doubtful cases.  
Additionally, we evaluated DNA methylation levels in BAL from patients with lung cancer 
(n=82) as compared to non-malignant lung diseases (n=29) (Table 1E). The methylation levels 
of those four markers were significantly higher in BAL fluid from cancer patients than non-
cancer patients (Fig. 4A). AUCs were significant for all four genes with the following values 
AUCBCAT1=0.80, AUCCDO1=0.65, AUCTRIM58=0.72 and AUCZNF177=0.66 (Fig. 4B). Combination of 
the four genes in a logistic regression model achieved a significant AUC of 0.85 (95% CI [0.78, 
0.93] p < 0.001), with an optimism-corrected value of 0.83 (Fig. 4C). Evaluation of the full range 
of predictions of the model is also shown (Fig. 4D). As in the case with BAS specimens, our 
epigenetic signature with diagnostic value may be highly valuable for doubtful patients with 
negative cytology.  
Validation of epigenetic biomarkers in non-invasive sputum samples 
Finally, the methylation level of these 4 markers was examined in additional non-invasive 
samples. Sputums samples from 72 lung cancer patients and 26 cancer-free individuals were 
considered for evaluation (Table 1F). Methylation levels were significantly higher in individuals 
with lung cancer for all the genes tested, except for CDO1 (Fig. 5A). Individual AUC values were 
AUCBCAT1=0.92, AUCCDO1=0.67, AUCTRIM58=0.67 and AUCZNF177=0.69 (Fig. 5B). The multivariable 
logistic regression model yielded an AUC value of 0.93 (95% CI [0.86, 1.0], p<0.001) (Fig. 5C). 
Sensitivity and specificity for the different threshold values of the model are depicted (Fig. 5D). 
This result suggests that our markers may be of high value to detect lung cancer even in non-
invasive specimens as sputum.  
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Discussion 
Lung cancer is the leading cause of cancer-related death worldwide with 1.3 million deaths 
annually, following data from the World Health Organization (WHO) in 2011. Late diagnosis in 
lung cancer is one of the main reasons that explain the extremely high mortality of this 
disease.  On one hand, screening by means of low-dose helical computed tomography (LDCT) 
has shown to reduce mortality in a large randomized trial (26), however the positive predictive 
value is still low. On the other hand, low sensitivity associated with minimally invasive 
cytologies is also a current hurdle for the accurate diagnosis of lung cancer. Thus, lung cancer 
diagnosis using minimally and non-invasive strategies is a major challenge to improve survival 
and its refinement is urgently needed to ameliorate the overall mortality figures for lung 
cancer worldwide. Here, we have searched for powerful biomarkers by using the two largest 
publicly available databases (FP7 Curelung and TCGA) (19) with high-throughput data coming 
from Infinium 450k arrays. Only stage I cancer cases were selected in order to identify the 
molecular changes associated to earlier steps of cancer evolution. We developed an 
integrative approach in order to identify the most discriminative marks leading to a final 
epigenetic signature consisting of top four selected genes: CDO1, BCAT1, TRIM58 and ZNF177. 
We conducted several validation steps using minimally and non-invasive cohorts to define a 
consistent epigenetic model useful for early lung cancer diagnosis valid for both major 
histological subtypes. This signature yielded a notably high specificity, one of the Achilles heels 
of LDCT and other methylation biomarkers (27,28) and also improved sensitivity, which is 
generally limited when using cytology for early lung cancer diagnosis.  
 
The current results highlight the relevance of DNA methylation changes in the natural history 
of lung cancer. CpG island hypermethylation of MGMT and GSTP1 has already proven useful 
for the chemotherapy response prediction in gliomas (29-31) and the screening of prostate 
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cancer, respectively (32,33). DNA methylation biomarkers have been proposed as promising 
candidates for early diagnosis (20,21) for several reasons: they are covalent and stable marks 
and they occur as early events in carcinogenesis, even in pre-tumoral stages such as 
adenomatous hyperplasia of the lung (34). Great efforts have been undertaken in identifying 
suitable DNA methylation markers to improve lung cancer diagnosis. However, only one 
biomarker —SHOX2 methylation— has been commercialized to date (35,36), although is not 
routinely used in the clinic.  
 
It is noteworthy to explain that cancer-specific DNA methylation in our selected biomarkers 
correlated with gene silencing in lung primary tumors. This fact suggests a potential functional 
role with biological implications in early stages of this pathological process (37). To our 
knowledge, there is a recent study addressing this issue with a different approach, taking 
benefit of the TCGA database: Wrangle et al. recently identified a three-gene panel (CDO1, 
HOXA9 and TAC1) for detecting NSCLC (12). They focused on re-expressed genes after 
treatment with demethylating agents and used TCGA as the only database incorporating all-
stage tumors, not only stage 1, among other differences.  Interestingly, despite using different 
strategies, CDO1 methylation was common for both studies. On the other hand, a study 
combining microRNA and gene expression arrays in three lung squamous cell carcinoma 
patients has also identified methylation-deregulated CDO1 (38). CDO1, cysteine dioxygenase 
type 1, has been postulated as a tumor suppressor gene silenced by promoter methylation in 
multiple human cancers, including breast, esophagus, lung, bladder and stomach (39). For the 
other genes, BCAT1 (Branched Chain Amino-Acid Transaminase 1) is a cytosolic enzyme that 
promotes cell proliferation though aminoacid catabolism (40) and high frequency of 
methylation on BCAT1 promoter in colorectal cancer has been reported (41). ZNF177 is a zinc 
finger transcription factor that has been reported to be methylation-silenced in gastric cancer 
cell lines (42). TRIM58, tripartite motif containing 58, is an E3 ubiquitin ligase superfamily 
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member that has already been patented as a potential epigenetic marker for detecting 
neoplastic cells originating from lung tissue of NSCLC patients (PCT/EP2012/061852). 
Moreover, it has also been reported hypermethylation of Trim58 promoter in hepatocytes 
derived from hepatitis B virus-related hepatocellular carcinoma (43). It is also worthy to 
indicate that we were very stringent in the selection of those genes, so alternative analyses 
from the same dataset may identify new DNA methylation biomarkers for lung cancer 
diagnosis in the future. 
 
The diagnostic value of the epigenetic signature was first validated by pyrosequencing in FFPE 
samples from non-small cell lung primary tumors. Results from our four-gene methylation 
signature presented high diagnostic accuracy and were extremely similar to those obtained 
from public databases. Importantly, we analyzed a total of 79 non-tumoral control tissues, and 
DNA methylation was almost negligible in the vast amount of samples, thus confirming 
previous results and encouraging the potential of the selected markers. Of note, in the study 
by Wrangle et al., the methylation status was assessed by using the MSP technique, in a 
smaller number of FFPE non-tumoral samples (12). We chose pyrosequencing, as targeted-
region validation technique, because is an affordable and quantitative method that 
counterbalances some weaknesses of previous and extensively used methods, due to its easy 
standardization and lower false positive rate (44). Moreover, it is a robust and quantitative 
method able to detect multiple CpGs not only in FFPE tissues but also in minimally and non-
invasive samples as biological fluids with potential use in daily basis clinical settings.  
 
The performance of the epigenetic model in these types of specimens, such as BAS, BAL and 
sputum was outstanding despite the limited number of tumoral cells compared to FFPE 
samples. The improvement of the diagnosis of lung cancer patients represents a major 
challenge. Our epigenetic model provides a balanced and flexible approach able to cater to 
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both extreme scenarios: the high sensitivity and low specificity of low dose CT in screening 
programs and the high specificity and low sensitivity of cytology (45,46) in respiratory 
specimens routinely used for lung cancer diagnosis. Our signature improves the predictions of 
cytology by providing a method for continuous predictions. Cytology is a useful dichotomized 
classifier producing two types of predictions: 100 % positive or 0% positive (100% negative). 
Therefore, the final output will be either a complete success or a total failure. In contrast, our 
signature based in a logistic regression model, represented by a nomogram, thus being able to 
produce a continuous range of predictions between 100% positive and 0% positive (47). That 
way, not all predictions are a complete success or a total failure, uncertainty can be measured 
for each prediction and errors are almost always lower (48). A clinician could take different 
actions according to the (un)certainty of the predictions, maybe performing additional tests in 
borderline cases. In a virtual situation where our model predicts two negative samples with 
different probability of being positive: such as 5% and 49%, the bimodal classifier predictor 
(cytology) would have output only absolute responses: negative and negative. Therefore, no 
information about uncertainty and chances of being positive for patient 1 (very low) and 
patient 2 (almost 50%) would have been delivered. The combination of current diagnostic 
protocol with new epigenetic nomograms will be of great help for diagnosis of lung cancer and 
consequently improving the outcome of lung cancer patients (49).  
 
In summary, we have identified and independently validated a powerful epigenetic signature 
diagnosis of lung cancer in minimally and non-invasive samples. Genome-wide DNA 
methylation analyses led us to identify 4 candidates that have been tested not only in publicly 
available datasets, but also in extensive and independent cohorts of respiratory samples. The 
herein identified epigenetic model, once it will be validated in intended of use samples such as 
in patients with suspicious indeterminate lung nodules, might be extremely helpful to solve 
these clinical issues with current diagnostic protocols and define more precise screening 
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programs for lung cancer. In addition, novel and more sensitive methods, currently in 
development, such as Methyl-Beaming or droplet digital PCR (50) could enhance their 
diagnostic value for the management of suspicious lung nodules in the clinic or within a 
program of lung cancer screening. 
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Table 1. Clinical characteristics of the invasive [Discovery (A), Validation (B) and Paraffin (C)] and minimally invasive [BAS (D), BALs (E) and Sputum (F)] cohorts.                                  
PATIENTS A. DISCOVERY COHORT B. TCGA VALIDATION COHORT C. PARAFFIN COHORT
  Tumor (n=237) Non-tumoral (n=25) Tumor (n=350) Non-tumoral (n=62) Tumor (n=122) Non-tumoral (n=79)
Age (years) 68 (38-90) 63.5 (39-86) 66.9 (33-90) 66.9 (40-86) 63.8 (40-80) 62.5 (42-85)
Gender  
     Male 131 (55.3%) 20 (80%) 190 (54.1%) 36 (58.0%) 108 (88.5%) 66 (83.5%)
     Female 106 (44.7%) 5 (20%) 160 (45.9%) 26 (42.0%) 14 (11.5%) 13 (16.5%) 
Smoking history  
     Current or former smoker 190 (80.1%) 24 (96%) 313 (89.4%) 55 (89.4%) 70 (57.4%) 71 (89.9%)
     Nonsmoker 25 (10.5%) 1 (4%) 32 (9.1%) 2 (9.1%) 36 (29.5%) 8 (10.1%)
     Unknown 22 (9.4%) 0 (0%) 5 (1.5%) 5 (1.5%) 16 (13.1%) 0 (0%)
Stage  
     I 237 (100%) 350 (100%)  122 (100%)
Histology  
     Adenocarcinoma 181 (76.4%) 217 (62.1%)  62 (50.8%)
     Squamous cell carcinoma 56 (23.6%) 133 (37.9%)  60 (49.2%)
Pack-years  40 (0-180) 54.4 (0-184) 46.7 (1-94.5) 46.4 (5-192) 35.9 (0-130) 46.7 (0-141)
 
Data are average (range) or number (%).  
PATIENTS D. BAS COHORT E.     BALs COHORT F.     SPUTUM COHORT
  Lung cancer patient  
(n=51) 
Cancer-free donor 
(n=29) 
Lung cancer patient  
(n=82) 
Cancer-free donor 
(n=29) 
Lung cancer patient  
(n=72) 
Cancer-free donor 
(n=26) 
Age (years) 65.6 (47-85) 64.0 (35-87) 62.1 (38-83) 57.5 (30-82) 65.1 (40-83) 52.7 (29-69)
Gender  
     Male 46 (90.2%) 16 (55.2%) 66 (80.4%) 19 (65.5%) 62 (86.1%) 17 (65.4%)
     Female 5 (9.8%) 10 (34.5%) 16 (19.6%) 9 (31.0%) 7 (9.7%) 9 (34.6%)
     Unknown 0 (0%) 3 (10.3%) 0 (0%) 1 (3.5%) 3 (4.2%)
Smoking history  
     Current or former smoker 45 (88.2%) 16 (55.2%) 42 (51.2%) 15 (51.7%) 62 (86.1%) 20 (76.9%)
     Nonsmoker 4 (7.8%) 8 (27.6%) 39 (47.5%) 12 (41.3%) 7 (9.7%) 6 (23.1%)
     Unknown 2 (4.0%) 5 (17.2%) 1 (1.3%) 2 (7%) 3 (4.2%) 0 (0%)
Stage  
     I 5 (9.8%) 17 (20.7%)  12 (16.7%)
     II 6 (11.8%) 8 (9.8%)  13 (18.0%)
     III 21 (41.2%)  20 (24.4%)  23 (32.0%)  
     IV 18 (35.3%) 18 (22.0%)  19 (26.4%)
    Unknown 1 (1.9%) 19 (23.1%)  5 (6.9%)
 Histology  
     Adenocarcinoma 17 (33.3%) 25 (30.5%)  38 (52.7%)
     Squamous cell carcinoma 19 (37.3%) 40 (48.8%)  24 (33.3%)
     Large cell carcinoma 2 (4.0%) 2 (2.4%)  2 (3%)
     Small cell carcinoma 2 (4.0%) 12 (14.6%)  5 (7%)
    NSCLC (NOS) 11 (21.4%) 3 (3.7%)  3 (4%)
Pack-years 49.6 (0-120) 32.4 (0-100) 45.5 (0-120) 26.3 (0-90) 49.1 (0-120) 24.1 (0-114)
 
Data are average (range) or number (%).NSCLC (NOS): Non-small cell lung cancer. Not otherwise specified 
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Figure Legends 
Figure 1. Epigenetic signature in lung primary tumor patients using genome-wide DNA 
methylation datasets. (A) DNA methylation levels of selected genes (Branched Chain 
Aminoacid Transaminase 1 -BCAT1-, Cysteine Dioxygenase type 1 -CDO1-, Tripartite Motif 
Containing 58 -TRIM58-, zinc finger protein 177 -ZNF177- and Crystallin, Gamma D -CRYGD-) in 
primary tumor samples from patients with lung cancer and non-tumoral  specimens using our 
FP7 Curelung dataset. (B) Validation of DNA methylation values using public available dataset 
from The Cancer Genome Atlas database (TCGA). (C) Expression values for the gene candidates 
using the TCGA database. P values for all the analyses were calculated using the two-sided 
Mann–Whitney U test. NT (light grey circle dots) stands for non-tumoral and T (dark grey 
square dots) for tumor. *** correspond to p<0.001. 
Figure 2. Epigenetic signature in paraffin samples using pyrosequencing. (A) DNA methylation 
levels of candidate genes in paraffin-embedded sections from patients with lung cancer and 
control donors. P values for all the analyses were calculated using the two-sided Mann–
Whitney U test. NT (light grey circle dots) stands for non-tumoral and T (dark grey square dots) 
for tumor. *** correspond to p<0.001. (B) ROC curves and area under the curve (AUC) with 
95% confidence intervals for the candidate genes.  
Figure 3. Epigenetic signature in bronchial aspirates using pyrosequencing. (A) DNA 
methylation levels in bronchial aspirates from patients with lung cancer and control donors. NT 
(light grey circle dots) stands for non-tumoral and T (dark grey square dots) for tumor. P values 
for all the analyses were calculated using the two-sided Mann–Whitney U test. *** 
corresponds to p<0.001. (B) ROC curves and areas under the curve (AUC) for the selected 
genes. (C)  The area under the curve (AUC) for the combined signature using a logistic 
regression model (D) Sensitivity and specificity profiles for the different possible cut-off values 
of the results from the logistic regression model.  
28 
 
Figure 4. Epigenetic signature in bronchioalveolar lavages using pyrosequencing. (A) DNA 
methylation levels in bronchioalveolar lavages from patients with lung cancer and control 
donors. NT (light grey circle dots) stands for non-tumoral and T (dark grey square dots) for 
tumor. P values for all the analyses were calculated using the two-sided Mann–Whitney U test. 
*** corresponds to p<0.001; * p<0.05. (B) ROC curves and areas under the curve (AUC) for the 
selected genes. (C) The area under the curve (AUC) for the combined signature using a logistic 
regression model (D) Sensitivity and specificity profiles for the different possible cut-off values 
of the results from the logistic regression model.  
Figure 5. Epigenetic signature in sputum samples using pyrosequencing. (A) DNA methylation 
levels in sputums from patients with lung cancer and control donors. NT (light grey circle dots) 
stands for non-tumoral and T (dark grey square dots) for tumor. P values for all the analyses 
were calculated using the two-sided Mann–Whitney U test. *** corresponds to p<0.001; ** 
p<0.01 and * p<0.05. (B) ROC curves and areas under the curve (AUC) for the selected genes. 
(C) The area under the curve (AUC) for the combined signature using a logistic regression 
model (D) Sensitivity and specificity profiles for the different possible cut-off values of the 
results from the logistic regression model.  
 
 
46 

 
